|
|
Photo by GoodLifeStudio/Getty Images
|
|
|
Among young adults who consume cannabis, use of higher potency-cannabis flower is positively associated with more use days and more grams of flower used per day, which is inconsistent with the notion that individuals titrate use of higher-potency cannabis.
|
|
|
|
|
| | Photo by pocketlight/Getty Images | | A review of 135 studies shows striking variation in daily illegal opioid consumption, with consumed morphine milligram equivalents about six times higher when supply is abundant and cheap compared to high-price illegal markets. These findings highlight the need for drug policy and treatment protocols to account for rising consumption intensities, especially in the fentanyl era. | |
|
|
|
| | Photo by Igor Alecsander/Getty Images | | Clinicians and policymakers are paying greater attention to ensuring individuals are receiving adequate buprenorphine dosages to treat their opioid use disorder effectively. Disproportionate reliance on cash payment for higher daily doses suggests that public and private insurers could facilitate access to such treatment when appropriate. | |
|
|
|
| | Photo by Antwon McMullen/Getty Images | | Between 2003 and 2018, cannabis involvement in suicides and deaths of undetermined intent increased in the U.S. People who had used cannabis were more likely to also have used opioids, while states with stricter cannabis policies saw lower rates of cannabis and opioid involvement in these deaths. | |
|
|
|
|
|
|
|
Contact
|
|
|
| Codirector, RAND Drug Policy Research Center; Senior Economist; Professor of Policy Analysis, RAND School of Public Policy |
|
| Codirector, RAND Drug Policy Research Center; Senior Policy Researcher; Professor of Policy Analysis, RAND School of Public Policy |
|
| RAND Europe Lead, RAND Drug Policy Research Center; Senior Analyst |
|
|
|
|